Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lavie Bio will offer Yalos™ (formerly Thrivus™) to farmers growing spring wheat, durum and barley across the US and Canada in 2024 REHOVOT, Israel , Nov. 28, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley

Evogene Ltd. (NASDAQ:EVGN ) Q3 2023 Earnings Conference Call November 15, 2023 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Amit Noam - Chief Executive Officer of Lavie Bio Nir Arbel - CPO of Evogene Conference Call Participants Ryan Mayer - Lake Street Capital Brian Wright - ROTH Capital Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) Q3 2023 Earnings Call Transcript

Conference call and webcast: today, November 15, 2023, 9:00 am ET REHOVOT, Israel, Nov. 15, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the third quarter period ended September 30, 2023.

Evogene Reports Third Quarter 2023 Financial Results

LAV321, discovered and optimized by Lavie Bio, delivered positive results in 2023 field trials across Europe and the US, protecting against downy mildew REHOVOT, Israel , Nov. 8, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results

Conference call scheduled for 9:00 AM ET REHOVOT, Israel , Nov. 2, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Wednesday, November 15, 2023.

Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023

Leveraging a grant from the Israel Innovation Authority, the alliance sets out to improve crustacean traits including growth rate, disease resistance, and environmental adaptation. HAZEVA and REHOVOT, Israel , Oct. 31, 2023 /PRNewswire/ -- Colors Farm Ltd, a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd.

Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology

REHOVOT, Israel , Oct. 18, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today provides an update to its investors and stakeholders amidst the ongoing security situation in Israel.

Evogene Provides Operational Update Amidst Current Security Situation in Israel

This first shipment, valued at approximately US$1 million, is part of a framework agreement with a world-leading oil and gas company REHOVOT, Israel , Sept. 27, 2023 /PRNewswire/ -- Casterra Ag Ltd.

Casterra Delivers First Shipment of Castor Seeds to Africa

Evogene (EVGN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Evogene (EVGN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Evogene Ltd. (NASDAQ:EVGN ) Q2 2023 Earnings Conference Call August 17, 2023 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Amit Noam - Chief Executive Officer of Lavie Bio Eyal Ronen - Chief Executive Officer of Casterra Yaron Eldad - Chief Financial Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) Q2 2023 Earnings Call Transcript

Evogene (EVGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.21 per share a year ago.

Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates

Conference call and webcast: today, August 17, 2023, 9:00 am ET REHOVOT, Israel , Aug. 17, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023.

Evogene Reports Second Quarter 2023 Financial Results

REHOVOT, Israel , Aug. 15, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Conference call scheduled for 9:00 AM ET REHOVOT, Israel , Aug. 1, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN)(TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the second quarter of 2023, on Thursday, August 17, 2023.

Evogene Schedules Second Quarter 2023 Financial Results Release & Conference Call for August 17, 2023

The new application, TargetSelector, streamlines target-protein discovery and enables researchers in various industries to identify novel targets for innovative products REHOVOT, Israel , July 25, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, is proud to announce the latest addition to its ChemPass AI tech-engine – a breakthrough technology for target-protein discovery.

Evogene's ChemPass AI Tech-Engine is Introduced with New Breakthrough Machine Learning Technology for Target-Protein Discovery

The results demonstrate the efficacy of Biomica's live bacterial consortia, BMC426 and BMC427, for the treatment of IBS REHOVOT, Israel , July 19, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program

REHOVOT, Israel , July 17, 2023 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced it has entered into securities purchase agreements with institutional investors (including SilverArc Capital Management, Altium Capital Management, LP and CVI Investments, Inc.) for the purchase and sale of 8,500,000 ordinary shares in a registered direct offering at a purchase price of $1.00 per ordinary share (the "offering").

Evogene Announces Pricing of US$8,500,000 Registered Direct Offering

Corteva Inc

Corteva to receive exclusive rights to further develop and commercialize Lavie Bio's lead product candidates for fruit rot and powdery mildew fungicide biologicals REHOVOT, Israel , July 17, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience

REHOVOT, Israel , July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd.

AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

Evogene's wholly-owned subsidiary Casterra Ag has received initial purchase orders worth $11.3 million for its proprietary castor plant seeds, which will be used for biofuel production in Africa. The orders come earlier than expected, as Evogene's CEO previously anticipated seed sales to begin in 2024. Castor oil is increasingly seen as a green biofuel in Europe, with EU regulations requiring 14% of transportation fuels to be biofuels by 2030.

Evogene's Subsidiary Casterra: $11.3M Sale Of Castor Plant Seeds May Be Tip Of Iceberg

Casterra will supply the castor seeds in 2023 for the cultivation of castor plants to produce oil for sustainable biofuel REHOVOT, Israel , July 3, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company and a subsidiary of Evogene Ltd.

Casterra Announces Additional $2.2 Million of Purchase Orders to Supply Castor Seeds for New African Territories

Casterra is expected to deliver the initial orders of its proprietary castor seeds, developed using Evogene's GeneRator AI tech engine, during 2023  REHOVOT, Israel , June 21, 2023 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company and a subsidiary of Evogene Ltd.

Casterra Signs a Framework Agreement with a World Leading Oil and Gas Company to Sell Its Castor Seeds for Sustainable Biofuel Production, with Initial Purchase Orders of $9.1 Million

The approval by the Canadian Food Inspection Agency triples Thrivus'™ sales territory REHOVOT, Israel , May 24, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Receives Canadian Regulatory Approval for Thrivus™, Expanding Global Reach

Evogene Ltd (NASDAQ:EVGN ) Q1 2023 Earnings Conference Call May 18, 2023 9:00 AM ET Company Participants Rachel Tamara - Evident, Head of Investor Relations Ofer Haviv - CEO & President Nir Arbel - Chief Product Officer Elran Haber - CEO, Biomica Ltd Yaron Eldad - CFO Conference Call Participants Brian Wright - ROTH MKM Ben Klieve - Lake Street Capital Markets Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by. Welcome to Evogene's First Quarter 2023 Results Conference Call.

Evogene Ltd (EVGN) Q1 2023 Earnings Call Transcript

Evogene (EVGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago.

News for Evogene Stock (EVGN)